Zimmer Biomet (ZBH) Stock Forecast & Price Target

$97.94 -0.98 (-0.99%)

As of 09/4/2026 03:58 PM Eastern

Compare

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 23 Analyst Ratings

Sell
2

Hold
14

Buy
7

Based on 23 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 23 analysts, 2 have given a sell rating, 14 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for ZBH.

Consensus Price Target

$104.42
6.62% Upside

According to the 23 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $104.42. The highest price target for ZBH is $130.00, while the lowest price target for ZBH is $90.00. The average price target represents a forecasted upside of 6.62% from the current price of $97.94.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ZBH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZBH Analyst Ratings Over Time

Type	Current Forecast 9/6/25 to 9/6/26	1 Month Ago 8/7/25 to 8/7/26	3 Months Ago 6/8/25 to 6/8/26	1 Year Ago 9/6/24 to 9/6/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)
Hold	14 Hold rating(s)	13 Hold rating(s)	12 Hold rating(s)	9 Hold rating(s)
Sell	2 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$104.42	$104.00	$102.70	$111.44
Forecasted Upside	6.62% Upside	7.73% Upside	17.58% Upside	5.55% Upside
Consensus Rating	Hold	Hold	Hold	Hold

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zimmer Biomet Stock vs. The Competition

Type	Zimmer Biomet	Healthcare Companies	Broader Market
Consensus Rating Score	2.26	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	6.62% Upside	928.71% Upside	14.03% Upside
News Sentiment Rating	Positive News See Recent ZBH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/25/2026	Zacks Research 5 of 5 stars		Upgrade	Strong Sell ➝ Hold
8/10/2026	Canaccord Genuity Group 3 of 5 stars	Caitlin Roberts Not Rated	Boost Target	Hold	$83.00 ➝ $100.00	+3.59%
8/6/2026	Truist Financial 3 of 5 stars	Richard Newitter 1 of 5 stars	Boost Target	Hold	$92.00 ➝ $106.00	+9.13%
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$104.00	+7.46%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$120.00	+21.89%
8/6/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$91.00 ➝ $93.00	-5.53%
8/6/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vik Chopra Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$96.00	-2.12%
8/6/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$101.00 ➝ $110.00	+12.15%
8/6/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$105.00 ➝ $110.00	+13.18%
8/5/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
Get the Latest News and Ratings for ZBH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.
8/4/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Sell (D+) ➝ Hold (C-)
5/28/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$95.00 ➝ $93.00	+12.16%
4/29/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Underweight	$100.00 ➝ $94.00	+13.32%
4/29/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$100.00 ➝ $95.00	+18.30%
4/29/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Outperform	$120.00 ➝ $105.00	+29.42%
4/29/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$98.00 ➝ $90.00	+11.43%
4/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Hold	$101.00	+8.44%
3/23/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
2/20/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy ➝ Market Perform
1/26/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
1/9/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$93.00	-1.14%
1/5/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$94.00 ➝ $120.00	+33.25%
11/5/2025	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$112.00	+28.01%
9/18/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ed Ridley-Day Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$130.00	+29.92%
8/8/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$104.00 ➝ $113.00	+15.02%
8/7/2025	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
5/6/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$115.00 ➝ $95.00	+4.11%
10/15/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$145.00 ➝ $135.00	+29.93%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:09 AM ET.

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 5, 2026. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

The stock is currently trading at $97.94, which is below the average analyst price target of $104.42, suggesting potential upside for investors who believe the market is undervaluing the company's recent performance.
Zimmer Biomet Holdings, Inc. recently reported earnings per share of $2.07 for the quarter, which exceeded the consensus estimate of $2.01, demonstrating the company's ability to outperform market expectations and drive shareholder value.
The company has a low beta of 0.47, indicating that its stock price is less volatile than the overall market, which can provide a more stable investment experience for risk-averse investors.
Zimmer Biomet Holdings, Inc. offers a dividend yield of 0.98%, providing a steady income stream for investors, with a recent quarterly dividend of $0.24 per share scheduled for payment.
Institutional investors, including Munich Reinsurance Co and Hsbc Holdings PLC, have recently acquired new positions in the company, signaling confidence in its long-term growth prospects and financial health.

Zimmer Biomet
Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

The stock has a P/E ratio of 23.83, which is higher than the market average, potentially indicating that the stock is overvalued relative to its earnings, especially given the current consensus rating of "Hold."
Short interest in Zimmer Biomet Holdings, Inc. has increased in recent months, with the percentage of shares shorted rising to 4.67% of the float, suggesting that some investors are betting against the stock's future performance.
Insider selling activity has been observed, with executives such as Sang Yi and Lori Winkler selling shares in 2026, which could signal a lack of confidence in the company's near-term prospects.
The company's revenue growth of 4.8% year-over-year in the most recent quarter is modest, and investors may be concerned about the pace of growth in a competitive medical device market.
Despite recent earnings beats, the company's net margin of 9.48% and return on equity of 13.12% may not be sufficient to justify the current valuation, particularly if growth slows in the coming quarters.

ZBH Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $104.42, with a high forecast of $130.00 and a low forecast of $90.00.

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 2 sell ratings, 14 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.

According to analysts, Zimmer Biomet's stock has a predicted upside of 6.62% based on their 12-month stock forecasts.

Over the previous 90 days, Zimmer Biomet's stock had 3 upgrades and 2 downgrades by analysts.

Zimmer Biomet has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, Needham & Company LLC, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, Truist Financial, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Zimmer Biomet less than other "healthcare" companies. The consensus rating score for Zimmer Biomet is 2.26 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how ZBH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zimmer Biomet Recommendations

MarketBeat monitors more than a dozen sources for Zimmer Biomet analyst ratings, with the most recent rating issued on 8/25/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Stock Forecast & Price Target

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ZBH Analyst Ratings Over Time

ZBH Analyst Recommendations By Month

ZBH Price Targets by Month

Zimmer Biomet Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

Zimmer Biomet
Bull Case

Zimmer Biomet
Bear Case

ZBH Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zimmer Biomet Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Stock Forecast & Price Target

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ZBH Analyst Ratings Over Time

ZBH Analyst Recommendations By Month

ZBH Price Targets by Month

Zimmer Biomet Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

Zimmer Biomet Bull Case

Zimmer Biomet Bear Case

ZBH Forecast - Frequently Asked Questions

What is Zimmer Biomet's forecast for 2026?

Should I buy or sell Zimmer Biomet stock right now?

Does Zimmer Biomet's stock price have much upside?

Has Zimmer Biomet been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Zimmer Biomet?

Do Wall Street analysts like Zimmer Biomet more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zimmer Biomet Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Zimmer Biomet
Bull Case

Zimmer Biomet
Bear Case